Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 6
2023 1
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Data on Osimertinib-Associated Cardiac Toxicity.
Agbarya A, Raphael A, Gantz Sorotsky H, Rottenberg Y, Šebek V, Radonjic D, Yakobson A, Arnon J, Shalata W. Agbarya A, et al. Among authors: raphael a. J Clin Med. 2025 Mar 5;14(5):1754. doi: 10.3390/jcm14051754. J Clin Med. 2025. PMID: 40095892 Free PMC article.
Body composition measures as a determinant of Alpelisib related toxicity.
Shachar E, Raphael A, Katz U, Kessner R, Shachar SS. Shachar E, et al. Among authors: raphael a. Breast Cancer Res Treat. 2024 Jul;206(2):369-376. doi: 10.1007/s10549-024-07315-9. Epub 2024 Apr 7. Breast Cancer Res Treat. 2024. PMID: 38584192 Free PMC article.
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).
Raphael A, Onn A, Holtzman L, Dudnik J, Urban D, Kian W, Cohen AY, Moskovitz M, Zer A, Bar J, Rabinovich NM, Grynberg S, Oedegaard C, Agbarya A, Peled N, Shochat T, Dudnik E. Raphael A, et al. Front Oncol. 2022 May 13;12:874712. doi: 10.3389/fonc.2022.874712. eCollection 2022. Front Oncol. 2022. PMID: 35646707 Free PMC article.
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).
Raphael A, Dudnik E, Hershkovitz D, Jain S, Olsen S, Soussan-Gutman L, Ben-Shitrit T, Dvir A, Nechushtan H, Peled N, Onn A, Agbarya A, On Behalf Of The Israel Lung Cancer Group. Raphael A, et al. J Clin Med. 2022 Apr 28;11(9):2475. doi: 10.3390/jcm11092475. J Clin Med. 2022. PMID: 35566609 Free PMC article.